References: Streptococcus pyogenes bloodstream infections, including toxic shock syndrome
Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA 1993;269(3):390-1. https://www.ncbi.nlm.nih.gov/pubmed/8418347
Balance Investigators, for the Canadian Critical Care Trials Group the Association of Medical Microbiology, Infectious Disease Canada Clinical Research Network, the Australian New Zealand Intensive Care Society Clinical Trials Group, the Australasian Society for Infectious Diseases Clinical Research Network, Daneman N, et al. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med 2024. https://www.ncbi.nlm.nih.gov/pubmed/39565030
Bruun T, Rath E, Madsen MB, Oppegaard O, Nekludov M, Arnell P, et al. Risk Factors and Predictors of Mortality in Streptococcal Necrotizing Soft-tissue Infections: A Multicenter Prospective Study. Clin Infect Dis 2021;72(2):293-300. https://www.ncbi.nlm.nih.gov/pubmed/31923305
Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis 2014;59(3):358-65. https://www.ncbi.nlm.nih.gov/pubmed/24785239
Kadri SS, Swihart BJ, Bonne SL, Hohmann SF, Hennessy LV, Louras P, et al. Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clin Infect Dis 2017;64(7):877-85. https://www.ncbi.nlm.nih.gov/pubmed/28034881
Linner A, Darenberg J, Sjolin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 2014;59(6):851-7. https://www.ncbi.nlm.nih.gov/pubmed/24928291